PL4013751T3 - Pochodne 2-hydroksycykloalkano-1-karbamoilu - Google Patents
Pochodne 2-hydroksycykloalkano-1-karbamoiluInfo
- Publication number
- PL4013751T3 PL4013751T3 PL20767476.3T PL20767476T PL4013751T3 PL 4013751 T3 PL4013751 T3 PL 4013751T3 PL 20767476 T PL20767476 T PL 20767476T PL 4013751 T3 PL4013751 T3 PL 4013751T3
- Authority
- PL
- Poland
- Prior art keywords
- hydroxycycloalkane
- carbamoyl derivatives
- carbamoyl
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/12—Triazine radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2019071921 | 2019-08-15 | ||
| PCT/EP2020/072865 WO2021028570A1 (en) | 2019-08-15 | 2020-08-14 | 2-hydroxycycloalkane-1-carbamoyl derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4013751T3 true PL4013751T3 (pl) | 2025-05-19 |
Family
ID=72355943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20767476.3T PL4013751T3 (pl) | 2019-08-15 | 2020-08-14 | Pochodne 2-hydroksycykloalkano-1-karbamoilu |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US12291519B2 (pl) |
| EP (1) | EP4013751B1 (pl) |
| JP (1) | JP7604457B2 (pl) |
| KR (1) | KR102832308B1 (pl) |
| CN (1) | CN114269737A (pl) |
| AU (1) | AU2020329609B2 (pl) |
| BR (1) | BR112021026829A2 (pl) |
| CA (1) | CA3147454A1 (pl) |
| ES (1) | ES3015725T3 (pl) |
| HR (1) | HRP20250372T1 (pl) |
| HU (1) | HUE070924T2 (pl) |
| IL (1) | IL289197B1 (pl) |
| MA (1) | MA56883B1 (pl) |
| MX (1) | MX2022001789A (pl) |
| PH (1) | PH12022550338A1 (pl) |
| PL (1) | PL4013751T3 (pl) |
| RS (1) | RS66695B1 (pl) |
| TW (1) | TWI864071B (pl) |
| UA (1) | UA128909C2 (pl) |
| WO (1) | WO2021028570A1 (pl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12404295B2 (en) | 2019-08-09 | 2025-09-02 | Idorsia Pharmaceuticals Ltd | (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives |
| JP7612663B2 (ja) | 2019-08-09 | 2025-01-14 | イドルシア・ファーマシューティカルズ・リミテッド | (2-アセタミジル)チオ-ベータ-d-ガラクトピラノシド誘導体 |
| AU2020338816A1 (en) | 2019-08-29 | 2022-04-14 | Idorsia Pharmaceuticals Ltd | Alpha-D-galactopyranoside derivatives |
| CN115244045A (zh) * | 2019-12-24 | 2022-10-25 | 糖模拟物有限公司 | 抑制半乳凝素-3的c-糖苷酮、醚和醇 |
| EP4225752B1 (en) | 2020-10-06 | 2024-12-11 | Idorsia Pharmaceuticals Ltd | Spiro derivatives of alpha-d-galactopyranosides |
| EP4237419A1 (en) | 2020-11-02 | 2023-09-06 | Idorsia Pharmaceuticals Ltd | Galectin-3 inhibiting 2-hydroxycycloalkane-1 -carbamoyl derivatives |
| IL304923A (en) * | 2021-02-09 | 2023-10-01 | Idorsia Pharmaceuticals Ltd | History of hydroxyheterocycloalkane-carbamoyl |
| ES3033422T3 (en) | 2021-03-03 | 2025-08-04 | Idorsia Pharmaceuticals Ltd | Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives |
| WO2022189459A2 (en) * | 2021-03-10 | 2022-09-15 | Galecto Biotech Ab | Novel galactoside inhibitor of galectins |
| JP2024517936A (ja) * | 2021-05-14 | 2024-04-23 | グリコミメティクス, インコーポレイテッド | ガレクチン-3阻害性c-グリコシド |
| US20240287121A1 (en) * | 2021-05-28 | 2024-08-29 | Glycomimetics, Inc. | Galectin-3 inhibiting c-glycoside oximes |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0100172D0 (sv) | 2001-01-22 | 2001-01-22 | Ulf Nilsson | New inhibitors against galectins |
| SE0401300D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel Galactoside Inhibitors of Galectins |
| SE0401301D0 (sv) * | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel 3-triazolyl-galactoside inhibitors of galectins |
| JP6055928B2 (ja) | 2012-10-10 | 2016-12-27 | ガレクティン・セラピューティクス・インコーポレイテッドGalectin Therapeutics, Inc. | 糖尿病性腎症および関連障害の処置のためのガラクトース分枝炭水化物化合物 |
| EP2914269B1 (en) | 2012-10-31 | 2020-07-29 | Galecto Biotech AB | Galactoside inhibitor of galectin-3 and its use for treating pulmonary fibrosis |
| JP6366598B2 (ja) * | 2012-11-15 | 2018-08-01 | タフツ ユニバーシティー | ガレクチンタンパク質阻害剤を用いて被験体の眼の血管新生または繊維症を処置し、調節し、または、予防する方法、組成物、およびキット |
| WO2016120403A1 (en) * | 2015-01-30 | 2016-08-04 | Galecto Biotech Ab | Alpha-d-galactoside inhibitors of galectins |
| CN109879859B (zh) | 2015-07-06 | 2022-01-25 | 吉利德科学公司 | Cot调节剂及其使用方法 |
| US10889610B2 (en) | 2016-07-12 | 2021-01-12 | Galecto Biotech Ab | Alpha-D-galactoside inhibitors of galectins |
| AU2018265813A1 (en) | 2017-05-12 | 2019-12-05 | Galectin Sciences, Llc | Compounds for the treatment of systemic insulin resistance disorders and the use thereof |
| CA3062648A1 (en) | 2017-05-12 | 2018-11-15 | Galectin Sciences, Llc | Compounds for the prevention and treatment of diseases and the use thereof |
| US11267811B2 (en) * | 2017-09-27 | 2022-03-08 | Bristol-Myers Squibb Company | Small molecule inhibitors of galectin-3 |
| US11072626B2 (en) | 2017-10-11 | 2021-07-27 | Bristol-Myers Squibb Company | Small molecule inhibitors of Galectin-3 |
| AU2018361991A1 (en) | 2017-10-31 | 2020-05-14 | Galectin Sciences, Llc | Selenogalactoside compounds for the treatment of systemic insulin resistance disorders and the use thereof |
| WO2020078808A1 (en) | 2018-10-15 | 2020-04-23 | Galecto Biotech Ab | Galactoside inhibitor of galectins |
| WO2020078807A1 (en) | 2018-10-15 | 2020-04-23 | Galecto Biotech Ab | Prodrug of galactoside inhibitors of galectins |
| CN113412267B (zh) | 2018-11-21 | 2025-06-27 | 格莱克特生物技术公司 | 半乳糖凝集素的α-D-半乳糖苷抑制剂 |
| JP7577682B2 (ja) | 2019-04-10 | 2024-11-05 | ブリストル-マイヤーズ スクイブ カンパニー | ガレクチン-3の低分子阻害剤 |
| CN114555620A (zh) | 2019-07-03 | 2022-05-27 | 格莱克特生物技术公司 | 半乳糖凝集素的新型半乳糖苷抑制剂 |
| CN114450282A (zh) | 2019-07-05 | 2022-05-06 | 格莱克特生物技术公司 | 半乳糖凝集素的新型半乳糖苷抑制剂 |
| JP7612663B2 (ja) | 2019-08-09 | 2025-01-14 | イドルシア・ファーマシューティカルズ・リミテッド | (2-アセタミジル)チオ-ベータ-d-ガラクトピラノシド誘導体 |
| US12404295B2 (en) | 2019-08-09 | 2025-09-02 | Idorsia Pharmaceuticals Ltd | (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives |
| AU2020338816A1 (en) | 2019-08-29 | 2022-04-14 | Idorsia Pharmaceuticals Ltd | Alpha-D-galactopyranoside derivatives |
| EP4225752B1 (en) | 2020-10-06 | 2024-12-11 | Idorsia Pharmaceuticals Ltd | Spiro derivatives of alpha-d-galactopyranosides |
| EP4237419A1 (en) | 2020-11-02 | 2023-09-06 | Idorsia Pharmaceuticals Ltd | Galectin-3 inhibiting 2-hydroxycycloalkane-1 -carbamoyl derivatives |
| IL304923A (en) | 2021-02-09 | 2023-10-01 | Idorsia Pharmaceuticals Ltd | History of hydroxyheterocycloalkane-carbamoyl |
| ES3033422T3 (en) | 2021-03-03 | 2025-08-04 | Idorsia Pharmaceuticals Ltd | Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives |
-
2020
- 2020-08-14 ES ES20767476T patent/ES3015725T3/es active Active
- 2020-08-14 WO PCT/EP2020/072865 patent/WO2021028570A1/en not_active Ceased
- 2020-08-14 CN CN202080057325.7A patent/CN114269737A/zh active Pending
- 2020-08-14 IL IL289197A patent/IL289197B1/en unknown
- 2020-08-14 PL PL20767476.3T patent/PL4013751T3/pl unknown
- 2020-08-14 TW TW109127800A patent/TWI864071B/zh active
- 2020-08-14 AU AU2020329609A patent/AU2020329609B2/en active Active
- 2020-08-14 PH PH1/2022/550338A patent/PH12022550338A1/en unknown
- 2020-08-14 BR BR112021026829A patent/BR112021026829A2/pt unknown
- 2020-08-14 JP JP2022508567A patent/JP7604457B2/ja active Active
- 2020-08-14 EP EP20767476.3A patent/EP4013751B1/en active Active
- 2020-08-14 HU HUE20767476A patent/HUE070924T2/hu unknown
- 2020-08-14 MX MX2022001789A patent/MX2022001789A/es unknown
- 2020-08-14 HR HRP20250372TT patent/HRP20250372T1/hr unknown
- 2020-08-14 CA CA3147454A patent/CA3147454A1/en active Pending
- 2020-08-14 US US17/634,512 patent/US12291519B2/en active Active
- 2020-08-14 UA UAA202200939A patent/UA128909C2/uk unknown
- 2020-08-14 MA MA56883A patent/MA56883B1/fr unknown
- 2020-08-14 KR KR1020227006817A patent/KR102832308B1/ko active Active
- 2020-08-14 RS RS20250349A patent/RS66695B1/sr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UA128909C2 (uk) | 2024-11-20 |
| AU2020329609B2 (en) | 2025-10-02 |
| EP4013751B1 (en) | 2025-01-22 |
| EP4013751A1 (en) | 2022-06-22 |
| MA56883B1 (fr) | 2025-04-30 |
| PH12022550338A1 (en) | 2023-02-06 |
| JP2022544248A (ja) | 2022-10-17 |
| HRP20250372T1 (hr) | 2025-06-06 |
| AU2020329609A1 (en) | 2022-02-24 |
| CN114269737A (zh) | 2022-04-01 |
| IL289197B1 (en) | 2025-10-01 |
| HUE070924T2 (hu) | 2025-07-28 |
| JP7604457B2 (ja) | 2024-12-23 |
| IL289197A (en) | 2022-02-01 |
| KR20220047585A (ko) | 2022-04-18 |
| EP4013751C0 (en) | 2025-01-22 |
| WO2021028570A1 (en) | 2021-02-18 |
| TW202115039A (zh) | 2021-04-16 |
| MX2022001789A (es) | 2022-03-11 |
| KR102832308B1 (ko) | 2025-07-10 |
| US20220324847A1 (en) | 2022-10-13 |
| US12291519B2 (en) | 2025-05-06 |
| BR112021026829A2 (pt) | 2022-02-22 |
| TWI864071B (zh) | 2024-12-01 |
| CA3147454A1 (en) | 2021-02-18 |
| RS66695B1 (sr) | 2025-05-30 |
| ES3015725T3 (en) | 2025-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3958977T (pt) | Derivados de camptotecina | |
| EP3994692C0 (en) | BINARY COMPUTING CELL IN MEMORY | |
| IL292161A (en) | New methylquinazolinone derivatives | |
| EP3833739A4 (en) | STRAIN OF AKKERMANSIA MUCINIPHILA | |
| EP4013751C0 (en) | 2-HYDROXYCYCLOALKANE-1-CARBAMOYL DERIVATIVES | |
| LT3830085T (lt) | Deuterinti lanifibranoro dariniai | |
| EP4077334C0 (en) | FUROINDAZOLE DERIVATIVES | |
| DK3768669T3 (da) | Piperazinazaspiroderivater | |
| EP4021904C0 (en) | ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | |
| EP3919491C0 (en) | AKT INHIBITOR | |
| EP3967649C0 (en) | LIPID NANOPARTICLE | |
| DK3823970T3 (da) | Yderligere substituerede triazoloquinoxalinderivater | |
| EP3742771C0 (en) | M2M SM-SR TO SM-DP NOTIFICATION | |
| DK3823971T3 (da) | Substituerede triazol-quinoxalin-derivater | |
| EP4034170A4 (en) | TGF-BETA RELATED POLYPEPTIDES | |
| DK3796975T3 (da) | Sulfonylaminobenzamidderivater | |
| EP3973348A4 (en) | HEAD MOUNT DISPLAYS | |
| EP3957391C0 (en) | AGITATOR | |
| EP4082837A4 (en) | Roof box | |
| EP3975220A4 (en) | Display panel | |
| EP3965638C0 (en) | VAGINAL SPECULUM | |
| EP3962498A4 (en) | Combination therapies | |
| DK3894410T3 (da) | Substituerede xanthinderivater | |
| DK3738452T3 (da) | Fordamper | |
| DK3770162T3 (da) | Dihydrochromenderivater |